Serum free light chains and multiple myeloma: Is it time to extend their application?

Uros MarkovicValerio LeottaDaniele TibulloRachele GiubboliniAlessandra RomanoVittorio Del FabroNunziatina Laura ParrinelloMaria Teresa CannizzaroFrancesco Di RaimondoConcetta Conticello

Published in: Clinical case reports (2020)

In nonsecretory, oligo-secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti-MM agents.

Keyphrases

multiple myeloma
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
smoking cessation